Financings in Brief: Micro Therapeutics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics, Inc.: Newly formed Genyx Medical subsidiary focusing on treatment of urologic and gynecologic disorders says it is "currently seeking an initial round of financing." Funding would be used to support product development, completion of preclinical testing of Micro's Embolyx polymer as a urethral bulking agent for incontinence under a cross-licensing agreement, "and initiation of human clinical trials." Heading the new unit as president and CEO will be Thomas Berryman, Micro's current chief financial officer. Embolyx, which consists of a biocompatible polymer and contrast agent dissolved in a solvent carrier for injection into the body, is currently under development by Micro for neurointerventional applications ("The Gray Sheet" Nov. 24, In Brief)...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.